A 40something woman was thought to be too young for glaucoma but more people below age 60 are being diagnosed with glaucoma ...

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ...

Glaucoma can silently damage your optic nerve, leading to irreversible vision loss. Learn the early signs, risk factors, and ...

Medical experts in Plateau State have raised serious concerns over the rate at which glaucoma is spreading in the state, with ...

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

India carries a significant share of the global glaucoma burden. Approximately 12 million people or more live with this disease in India, which is one of the leading causes of blindness. But almost 90 ...

Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.

Glaucoma is a leading cause of irreversible blindness worldwide and often goes undiagnosed until vision loss is advanced.

Glaucoma develops when fluid inside the eye doesn’t drain properly, causing pressure to build up over time and damage the ...

Explore the silent thief of sight: glaucoma. This article sheds light on the urgent need for awareness and action to prevent ...

As the elderly population grows, the number of glaucoma patients continues to rise, with a notable increase observed among individuals in their 20s to 40s, necessitating heightened caution. Glaucoma ...

Scientists found immune cells (resident macrophages) help regulate eye pressure by keeping the eye’s drainage system clear.